ProMIS Neurosciences Inc. is a clinical-stage biopharmaceutical company developing antibody therapies for neurodegenerative diseases including Alzheimer's disease (AD), ALS, Parkinson's disease, and others. Its lead product PMN310 is a monoclonal antibody targeting toxic misfolded amyloid-beta oligomers in AD, currently in a Phase 1b clinical trial (PRECISE-AD). The company uses its proprietary EpiSelectTM computational platform to identify disease-specific epitopes on misfolded proteins for selective therapeutic targeting.
Q2 FY2026 — expected 2026-09-17
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-25 | 2025-12-31 | 0001104659-26-034554 | EDGAR | 95K words |
| 2025-03-31 | 2024-12-31 | 0001558370-25-004068 | EDGAR | 94K words |
| 2024-04-01 | 2023-12-31 | 0001558370-24-004532 | EDGAR | 92K words |
| 2023-03-08 | 2022-12-31 | 0001558370-23-003167 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-13 | 2026-06-30 | 0001104659-26-095895 | EDGAR | 21K words |
| 2025-11-12 | 2025-09-30 | 0001104659-25-109719 | EDGAR | 25K words |
| 2025-08-13 | 2025-06-30 | 0001558370-25-011299 | EDGAR | 23K words |
| 2025-05-12 | 2025-03-31 | 0001558370-25-007255 | EDGAR | 19K words |
| 2024-11-14 | 2024-09-30 | 0001558370-24-015634 | EDGAR | 24K words |
| 2024-08-08 | 2024-06-30 | 0001558370-24-011476 | EDGAR | 21K words |
| 2024-05-14 | 2024-03-31 | 0001558370-24-008145 | EDGAR | 18K words |
| 2023-11-14 | 2023-09-30 | 0001558370-23-019048 | EDGAR | 21K words |
| 2023-08-14 | 2023-06-30 | 0001558370-23-014914 | EDGAR | 19K words |
| 2023-05-15 | 2023-03-31 | 0001558370-23-009954 | EDGAR | 18K words |
| 2022-11-14 | 2022-09-30 | 0001104659-22-117657 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001104659-22-089668 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-13 | 0001104659-26-095905 | EDGAR | 2K words |
| 2026-07-28 | 0001104659-26-087269 | EDGAR | 3K words |
| 2026-03-25 | 0001104659-26-034162 | EDGAR | 3K words |
| 2026-01-30 | 0001104659-26-008325 | EDGAR | 1K words |
| 2025-12-16 | 0001104659-25-121627 | EDGAR | 1K words |
| 2025-11-24 | 0001104659-25-115182 | EDGAR | 1K words |
| 2025-11-19 | 0001104659-25-113978 | EDGAR | 1K words |
| 2025-11-12 | 0001104659-25-109714 | EDGAR | 3K words |
| 2025-10-24 | 0001104659-25-102137 | EDGAR | 2K words |
| 2025-09-30 | 0001104659-25-095032 | EDGAR | 3K words |
97 total filings indexed. 71 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001374339 |
| Ticker | PMN |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | Z4 |
| Website | https://www.promisneurosciences.com |
| Listed | 2005-09-30 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/PMN (~200 tokens, structured JSON with cryptographic provenance)